- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme, GBM, Brain Cancer
- Interventions
- VAL-083, Dianhydrogalactitol
- Drug
- Lead sponsor
- Kintara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cutaneous Breast Cancer
- Interventions
- REM-001 photodynamic therapy
- Combination Product
- Lead sponsor
- Kintara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- New York, New York • The Bronx, New York
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Glioma, GBM, Brain Cancer
- Interventions
- VAL-083, Dianhydrogalactitol, Physician's Choice of Salvage Therapy - temozolomide, Physician's Choice of Salvage Therapy - lomustine, Physician's Choice of Salvage Therapy - carboplatin
- Drug
- Lead sponsor
- DelMar Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Francisco, California • Rochester, Minnesota + 2 more
- Conditions
- Ovarian Cancer
- Interventions
- VAL-083, Dianhydrogalactitol
- Drug
- Lead sponsor
- DelMar Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Detroit, Michigan • Nashville, Tennessee
- Conditions
- Glioblastoma
- Interventions
- Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
- Drug · Radiation · Biological
- Lead sponsor
- Global Coalition for Adaptive Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme, GBM, Brain Cancer
- Interventions
- VAL-083 (Dianhydrogalactitol)
- Drug
- Lead sponsor
- Kintara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 5
- States / cities
- San Francisco, California • Denver, Colorado • Sarasota, Florida + 2 more